![Headshot of Andrew Foxley, Vice President, Franchise Head, Late Oncology R&D at AstraZeneca.](/content/dam/az/our-company/ambassadors/Andrew%20Foxley%20updated.png/jcr:content/renditions/cq5dam.web.{width}.Andrew%20Foxley%20updated.png)
I serve as Vice President and Franchise Head in Late Oncology R&D at AstraZeneca. In my current role, I lead the cross-functional R&D Franchise for development and launch of two of our key late stage oncology molecules: capivasertib and AZD9833. As part of that I also lead the Global Product Team for capivasertib.
Having spent more than 30 years in a pharmaceutical research setting, my experience in medicines development spans the cardiovascular and oncology therapeutic areas across all phases of drug development. In oncology I have worked on projects studying a range of tumour types including breast, prostate, lung, gastrointestinal, acute myeloid leukaemia and diffuse large B-cell lymphoma.
I joined AstraZeneca Clinical Operations in 2003 and have since held positions in both clinical operations and strategic drug development with increasing levels of responsibilities including development and delivery of a wide range of international drug development programmes. In these roles I have found tremendous value in partnering with external experts and throughout my career, I have organised and chaired corporate and academic advisory boards and served as secretary to several academic steering committees.
Before joining AstraZeneca, I was an Executive Director and Board Member at NCRL, a specialist contract research organisation specialising in the design and delivery of large-scale cardiovascular studies in which I played a leading role in developing the enterprise from a university spin-off company.
Being connected with the external research community is really important to me and I hold a number of honorary positions outside AstraZeneca including chair of the New Medicines and Data Strategic Leadership Group at the Association of the British Pharmaceutical Industry, co-chair of the UK Clinical Pharmacology Skills Alliance, and chair of the UK Clinical Pharmacology Trailblazer Apprenticeship Group.
At AstraZeneca, we are committed to pushing new boundaries in oncology research and helping to speed the delivery of high-quality, targeted medicines to patients. I am passionate about translating scientific research into outcomes that improve the lives of patients.
![](/content/dam/az/our-company/ambassadors/Andrew Foxley.png/jcr:content/renditions/cq5dam.web.100.square.Andrew Foxley.png)
CURRENT ROLE
2019 – 2020
2017 – 2019
2015 – 2017